Trial Profile
A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD and/or HSDD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2021
Price :
$35
*
At a glance
- Drugs Bremelanotide (Primary)
- Indications Female sexual dysfunction
- Focus Therapeutic Use
- Sponsors Palatin Technologies
- 30 Apr 2018 Results assessing age and weight subgroup analysis from 2 phase 3 studies (RECONNECT) and one phase 2 study (profile: 201617) presented at the 66th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists
- 01 May 2014 Responder analysis published in the Obstetrics and Gynecology.
- 01 Mar 2013 Results were presented at the International Society for the Study of Women's Sexual Health (ISSWSH) conference in March 2013.